Increased urinary excretion of C-telopeptides of type II collagen (CTX-II) predicts cartilage loss over 21 months by MRI

Osteoarthritis and Cartilage

Volumn 17, Issue 3, 2009, Pages 384-389

  Dam, E B ^a   Byrjalsen, I ^a   Karsdal, M A ^a   Qvist, P ^a   Christiansen, C ^a  

^a NORDIC BIOSCIENCE A S   (Denmark)

Author keywords

Cartilage; Collagen type II; MRI; Prognostic; Volume

Indexed keywords

CARBOXY TERMINAL TELOPEPTIDE; COLLAGEN TYPE 2;

ADULT; ARTICLE; CARTILAGE; CONTROLLED STUDY; DISEASE COURSE; FEMALE; FEMUR; FOLLOW UP; HUMAN; JOINT CAVITY; KNEE OSTEOARTHRITIS; KNEE RADIOGRAPHY; MAJOR CLINICAL STUDY; MALE; NUCLEAR MAGNETIC RESONANCE IMAGING; NUCLEAR MAGNETIC RESONANCE SCANNER; OSTEOLYSIS; PRIORITY JOURNAL; PROGNOSIS; TIBIA; URINALYSIS; URINARY EXCRETION;

AGED; BIOLOGICAL MARKERS; CARTILAGE, ARTICULAR; COLLAGEN TYPE II; DISEASE PROGRESSION; FEMALE; HUMANS; LONGITUDINAL STUDIES; MAGNETIC RESONANCE IMAGING; MALE; MIDDLE AGED; OSTEOARTHRITIS, KNEE; PEPTIDES; PREDICTIVE VALUE OF TESTS;

EID: 60249088275     PISSN: 10634584     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.joca.2008.07.009     Document Type: Article

References (33)

1. Berenbaum F. The quest for the Holy Grail: a disease-modifying osteoarthritis drug. Arthritis Res Ther 9 6 (2007) 111
2. Bingham III C.O., Buckland-Wright J.C., Garnero P., Cohen S.B., Dougados M., Adami S., et al. Risedronate decreases biochemical markers of cartilage degradation but does not decrease symptoms or slow radiographic progression in patients with medial compartment osteoarthritis of the knee: results of the two-year multinational knee osteoarthritis structural arthritis study. Arthritis Rheum 54 11 (2006) 3494-3507
3. Spector T.D., Conaghan P.G., Buckland-Wright J.C., Garnero P., Cline G.A., Beary J.F., et al. Effect of risedronate on joint structure and symptoms of knee osteoarthritis: results of the BRISK randomized, controlled trial [ISRCTN01928173]. Arthritis Res Ther 7 (2005) R625-R633
4. Clegg D.O., Reda D.J., Harris C.L., Klein M.A., O'Dell J.R., Hooper M.M., et al. Glucosamine, chondroitin sulfate, and the two in combination for painful knee osteoarthritis. N Engl J Med 354 8 (2006) 795
5. Abramson S.B., Attur M., and Yazici Y. Prospects for disease modification in osteoarthritis. Nat Clin Pract Rheumatol 2 6 (2006) 304-312
6. Karsdal M.A., Leeming D., Dam E.B., Henriksen K., Alexandersen P., Pastoureau P., et al. Should subchondral bone turnover be targeted when treating osteoarthritis?. Osteoarthritis Cartilage 16 6 (2008) 638-646
7. Bauer D.C., Hunter D.J., Abramson S.B., Attur M., Corr M., Felson D., et al. Classification of osteoarthritis biomarkers: a proposed approach. Osteoarthritis Cartilage 14 8 (2006) 723-727
8. Schaller S., Henriksen K., Hoegh-Andersen P., Sondergaard B.C., Sumer E.U., Tanko L.B., et al. In vitro, ex vivo, and in vivo methodological approaches for studying therapeutic targets of osteoporosis and degenerative joint diseases: how biomarkers can assist?. Assay Drug Dev Technol 3 5 (2005) 553-580
9. Karsdal M.A., Sumer E.U., Wulf H., Madsen S.H., Christiansen C., Fosang A.J., et al. Induction of increased cAMP levels in articular chondrocytes blocks matrix metalloproteinase-mediated cartilage degradation, but not aggrecanase-mediated cartilage degradation. Arthritis Rheum 56 5 (2007) 1549-1558
10. Reijman M., Hazes J.M.W., Bierma-Zeinstra S.M.A., Koes B.W., Christgau S., Christiansen C., et al. A new marker for osteoarthritis: cross-sectional and longitudinal approach. Arthritis Rheum 50 8 (2004) 2471-2478
11. Meulenbelt I., Kloppenburg M., Kroon H.M., Houwing-Duistermaat J.J., Garnero P., Hellio-Le Graverand M.P., et al. Clusters of biochemical markers are associated with radiographic subtypes of osteoarthritis (OA) in subject with familial OA at multiple sites. The GARP study. Osteoarthritis Cartilage 15 4 (2007) 379-385
12. Peterfy C.G., Guermazi A., Zaim S., Tirman P.F.J., Miaux Y., White D., et al. Whole-Organ Magnetic Resonance Imaging Score (WORMS) of the knee in osteoarthritis. Osteoarthritis Cartilage 12 3 (2004) 177-190
13. Stammberger T., Eckstein F., Englmeier K.H., and Reiser M. Determination of 3D cartilage thickness data from MR imaging: computational method and reproducibility in the living. Magn Reson Med 41 3 (1999) 529-536
14. Grau V., Mewes A.U.J., Alcaniz M., Kikinis R., and Warfield S.K. Improved watershed transform for medical image segmentation using prior information. IEEE Trans Med Imaging 23 4 (2004) 447-458
15. Dam E.B., Folkesson J., Pettersen P.C., and Christiansen C. Automatic morphometric cartilage quantification in the medial tibial plateau from MRI for osteoarthritis grading. Osteoarthritis Cartilage 15 7 (2007) 808-818
16. Qazi A.A., Folkesson J., Pettersen P.C., Karsdal M.A., Christiansen C., and Dam E.B. Separation of healthy and early osteoarthritis by automatic quantification of cartilage homogeneity. Osteoarthritis Cartilage 15 10 (2007) 1199-1206
17. Verheugen G. Commission directive 2005/28/ec laying down principles and guidelines for good clinical practice as regards investigational medicinal products for human use, as well as the requirements for authorization of the manufacturing or importation of such products. Official Journal of the European Union (2005) 13-19 Legislation 091
18. Peterfy C., Li J., Zaim S., Duryea J., Lynch J.A., Miaux Y., et al. Comparison of fixed-flexion positioning with fluoroscopic semi-flexed positioning for quantifying radiographic joint-space width in the knee: test-retest reproducibility. Skeletal Radiol 32 3 (2003) 128-132
19. Kellgren J.H., and Lawrence J.S. Radiological assessment of osteo-arthrosis. Ann Rheum Dis 16 4 (1957) 494-501
20. Folkesson J., Dam E.B., Olsen O.F., Pettersen P.C., and Christiansen C. Segmenting articular cartilage automatically using a voxel classification approach. IEEE Trans Med Imaging 26 1 (2007) 106-115
21. Jung M., Christgau S., Lukoschek M., Henriksen D., and Richter W. Increased urinary concentration of collagen type II C-telopeptide fragments in patients with osteoarthritis. Pathobiology 71 2 (2004) 70-76
22. Garnero P., Gineyts E., Christgau S., Finck B., and Delmas P.D. Association of baseline levels of urinary glucosyl-galactosyl-pyridinoline and type II collagen C-telopeptide with progression of joint destruction in patients with early rheumatoid arthritis. Arthritis Rheum 46 1 (2002) 21-30
23. Garnero P., Peterfy C., Zaim S., and Schoenharting M. Bone marrow abnormalities on magnetic resonance imaging are associated with type II collagen degradation in knee osteoarthritis: a three-month longitudinal study. Arthritis Rheum 52 9 (2005) 2822-2829
24. Garnero P., Ayral X., Rousseau J.C., Christgau S., Sandell L.J., Dougados M., et al. Uncoupling of type II collagen synthesis and degradation predicts progression of joint damage in patients with knee osteoarthritis. Arthritis Rheum 46 10 (2002) 2613-2624
25. Henrotin Y., Addison S., Kraus V., and Deberg M. Type II collagen markers in osteoarthritis: what do they indicate?. Curr Opin Rheumatol 19 5 (2007) 444-450
26. Mazières B., Garnero P., Gueguen A., Abbal M., Berdah L., Lequesne M., et al. Molecular markers of cartilage breakdown and synovitis at baseline as predictors of structural progression of hip osteoarthritis. The ECHODIAH Cohort. Br Med J 65 3 (2006) 354
27. Sharif M., Kirwan J., Charni N., Sandell L.J., Whittles C., and Garnero P. A 5-yr longitudinal study of type IIA collagen synthesis and total type II collagen degradation in patients with knee osteoarthritis - association with disease progression. Rheumatology 46 6 (2007) 938
28. Mazzuca S.A., Brandt K.D., Eyre D.R., Katz B.P., Askew J., and Lane K.A. Urinary levels of type II collagen C-telopeptide crosslink are unrelated to joint space narrowing in patients with knee osteoarthritis. Ann Rheum Dis 65 8 (2006) 1055-1059
29. Garnero P., Charni N., Juillet F., Conrozier T., and Vignon E. Increased urinary type II collagen helical and C telopeptide levels are independently associated with a rapidly destructive hip osteoarthritis. Ann Rheum Dis 65 12 (2006) 1639-1644
30. Garnero P., Mazieres B., Gueguen A., Abbal M., Berdah L., Lequesne M., et al. Cross-sectional association of 10 molecular markers of bone, cartilage, and synovium with disease activity and radiological joint damage in patients with hip osteoarthritis: the ECHODIAH cohort. J Rheumatol 32 4 (2005) 697-703
31. Bruyere O., Collette J., Kothari M., Zaim S., White D., Genant H., et al. Osteoarthritis, magnetic resonance imaging, and biochemical markers: a one year prospective study. Ann Rheum Dis 65 8 (2006) 1050-1054
32. Eckstein F., Cicuttini F., Raynauld J.P., Waterton J.C., and Peterfy C. Magnetic resonance imaging (MRI) of articular cartilage in knee osteoarthritis (OA): morphological assessment. Osteoarthritis Cartilage 14 Suppl 1 (2006) 46-75
33. Garnero P., Aronstein W.S., Cohen S.B., Conaghan P.G., Cline G.A., Christiansen C., et al. Relationships between biochemical markers of bone and cartilage degradation with radiological progression in patients with knee osteoarthritis receiving risedronate: the Knee Osteoarthritis Structural Arthritis randomized clinical trial. Osteoarthritis Cartilage 16 6 (2008) 660-666